Tag: BioNTech

The numbers tell a stark story of transition. BioNTech’s Covid vaccine revenue is sliding toward a projected €2.0-2.3 billion for ...

The clock is ticking for BioNTech. After a 30-day rally that has pushed its stock up 23% to €92.70, the ...

The numbers coming out of BioNTech’s pancreatic cancer study are the kind that make oncologists sit up. Seven out of ...

A resurgence in biotech sentiment, driven by sector-wide deal speculation and clinical breakthroughs, is providing a powerful tailwind for BioNTech ...

Investors are bracing for a pivotal fortnight at BioNTech SE, with a first-quarter earnings report and a consequential shareholder meeting ...

All eyes are on May 5th. When BioNTech reports its first-quarter earnings, investors will scrutinize more than just revenue from ...

Positive clinical results for a late-stage cancer drug candidate have strengthened BioNTech's strategic pivot away from its pandemic-era business. The ...

Market confidence in BioNTech is being tested as analysts from prominent firms revise their outlooks downward. Leerink Partners has taken ...

As BioNTech navigates a pivotal transition away from its pandemic-era revenue, the company is asking its shareholders to approve a ...

BioNTech is methodically moving beyond its pandemic legacy. A series of recent strategic decisions—from facility closures and halted trials to ...